Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapy reduction in rheumatoid arthritis patients in sustained remission
2009-015740-42Phase 3Terminated
- Sponsor
- Universitätsklinikum Erlangen
- Start
- Jan 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methotrexate, prednisolone, adalimumab, etanercept, infliximab and 8 more in rheumatoid arthritis (RA) (2 arms), sponsored by Universitätsklinikum Erlangen. Primary endpoint: Number of patients in each group still in remission after twelve months. Started Jan 2010; status: terminated.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2009-015740-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015740-42.